The section of Medical Oncolgy at the University of Verona conducts several clinical trials to test new treatments for different cancers with a particular interest in gastrointestinal tumors.

These clinical trials are conducted in different phases from phase I to III. Each phase tests specific aspects of experimental therapies, such as dosage, toxicity and effectiveness in comparison to standard treatments.

This is a partial list of the clinical trials active and/or recruiting at our center:

Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer

Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

- Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

- INCB 62079-101 A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

INCB 54828-202 Studio di fase 2, in aperto, a braccio singolo, multicentrico per valutare l’efficacia e la sicurezza di INCB054828 nei soggetti con colangiocarcinoma in stadioavanzato/metastatico o non resecabile chirurgicamente, incluse le traslocazioni del FGFR2, che non hanno risposto a precedenti terapie

- CRC2017_01: Studio di Fase II di Irinotecan Liposomiale (Nal-IRI) in associazione a 5-fluorouracile, acido levofolinico e Oxaliplatino in pazienti con tumore del pancreas resecabile “nITRo trial”

- I8X-MC-JECA_A Phase 1 Study of LY3200882 in Patients with Solid Tumors
C1: PDL1 inhibitor (LY3300054) in nonresectable solid tumors including advanced nonresectable
hepatocellular carcinoma (HCC) e C3: cisplatin and radiation therapy in head and neck cancers (first-line)